Stem Cell ReportsNeurosciencePeer-reviewed journal article
The LRRK2 kinase substrates Rab8a and Rab10 contribute complementary but distinct disease-relevant phenotypes in human neurons
Adamantios MamaisiD, Anwesha SanyaliD, Austin Fajfer, Catherine G. Zykoski, Michael Guldin, Alexis Riley-DiPaoloiD, Nitya SubrahmanianiD, Whitney S. Gibbs, Steve LiniD, Matthew J. LaVoieiD
Abstract
Mutations in the LRRK2 gene cause familial Parkinsons disease presenting with pleomorphic neuropathology that can involve -synuclein or tau accumulation. LRRK2 mutations are thought to converge toward a pathogenic increase in LRRK2 kinase activity. A subset of small Rab GTPases have been identified as LRRK2 substrates, with LRRK2-dependent phosphorylation resulting in Rab inactivation. We used CRISPR/Cas9 genome editing to generate a novel series of isogenic iPSC lines deficient in the two most well validated LRRK2 substrates, Rab8a and Rab10, from two independent, deeply phenotyped healthy control lines. Thorough characterization of NGN2-induced neurons revealed divergent effects of Rab8a and Rab10 deficiency on lysosomal pH, LAMP1 association with Golgi, -synuclein insolubility and tau phosphorylation, while parallel effects on lysosomal numbers and Golgi clustering were observed. Our data demonstrate largely antagonistic effects of genetic Rab8a or Rab10 inactivation which provide discrete insight into the pathologic features of their biochemical inactivation by pathogenic LRRK2 mutation. HighlightsO_LIRab8a and Rab10 deficiency induce lysosomal and Golgi defects C_LIO_LIRab8a and Rab10 deficiency induce opposing effects on lysosomal pH C_LIO_LIRab8a KO and Rab10 KO neurons show divergent effects on synuclein and tau proteostasis C_LIO_LIInactivation of different Rab GTPases can induce distinct disease-relevant phenotypes C_LI
- organism: human
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein structure prediction
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 18
- FWCI
- 4.28
- Field percentile
- top 5%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies
Silas A. Buck, Tuyana B. Malankhanova, … Laurie H. Sanders·Acta NeuropathologicaPeer-reviewed·Oct 23, 2025
- Endogenous Rab29 does not impact basal or nigericin and monensin stimulated LRRK2 pathway activity
Alexia F. Kalogeropulou, Jordana B. Freemantle, … Dario R. Alessi·bioRxiv·Jun 8, 2020
- Neurodegeneration caused by LRRK2-G2019S requires Rab10 in select dopaminergic neurons
Stavroula Petridi, C. Adam Middleton, … Christopher J. H. Elliott·bioRxiv·Mar 22, 2019
- Distinct roles for RAB10 and RAB29 in pathogenic LRRK2-mediated endolysosomal trafficking alterations
P. Rivero-Rios, M. Romo-Lozano, … S. Hilfiker·bioRxiv·Jun 20, 2020
- Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation
Tomoki Kuwahara, Kai Funakawa, … Takeshi Iwatsubo·Neurobiology of DiseasePeer-reviewed·Sep 9, 2020
- RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors
D. Dou, J. Aiken, E. L. F. Holzbaur·bioRxiv·Jul 25, 2023